Novo Nordisk Shares Plunge After Warning of Sharp Sales Decline Amid Pricing and Competition Pressures

Copenhagen | EcoPulse24
Novo Nordisk shares fell sharply during Tuesday trading after the company missed market expectations and issued guidance pointing to a decline in sales in 2026, reflecting mounting competitive pressures and a price war in the obesity drug market.

The company stated that its sales could fall by as much as 13% this year, impacted by price reductions on its flagship weight-loss drugs amid increased competition from major pharmaceutical firms and the expansion of lower-cost alternatives, as well as U.S. government pressure to lower drug costs.

The stock dropped nearly 20% at the opening of trading in Copenhagen, marking its steepest daily loss since July. The company’s market value fell to about $215 billion, down from over $600 billion in 2024.

This performance comes as the U.S. market is seeing a shift in market share toward competitors, alongside decisions to lower obesity drug prices within government health insurance programs, set to take effect from 2027. On the other hand, the company confirmed that the launch of the oral version of Wegovy in the United States has had a strong start, attracting a broad new user base, which supports its medium-term expansion strategy.

Novo Nordisk also announced a share buyback program worth up to 15 billion Danish kroner, along with management changes aimed at enhancing operational efficiency amid margin pressures.

EcoPulse24 Analysis
The sharp drop reflects a rapid repricing of Novo Nordisk’s growth prospects as the obesity drug market shifts from exceptional growth to open price competition. Despite strong structural demand for weight-loss treatments, accelerating competition and regulatory interventions are pressuring short-term revenues. The company’s future performance will depend on its ability to offset price declines by expanding its patient base and accelerating innovation, particularly in new formulations and international markets.